Table 1.
Published reports on PKR and Alzheimer’s disease
| Report | Sample | Results |
|---|---|---|
| Chang et al. 2002 [45] | Brain | pPKR neuronal accumulation |
| Peel et al. 2003 [39] | Brain | pPKR neuronal accumulation |
| Onuki et al. 2004 [32] | Brain | pPKR neuronal accumulation |
| Paccalin et al. 2006 [71] | PBL | pPKR increased level |
| Page et al. 2006 [40] | Brain | pPKR increased concentration |
| Bullido et al. 2008 [74] | DNA | PKR gene association |
| Damjanac et al. 2009 [72] | PBL | PKR-dependent increases in P53, Redd1 |
| Couturier et al. 2010 [35] | PBL | PKR control of inflammation |
| Bose et al. 2011 [47] | Brain | Co-localization of pPKR and ptau |
| Paquet et al. 2012 [69] | Brain | Increased levels of PKR activator PACT |
| Mouton-Liger et al. 2012 [76] | CSF | Increased levels of PKR and pPKR |
| Badia et al. 2013 [73] | PBL | Increased levels of PKR RNA in ApoE4 patients |
| Dumurgier et al. 2013 [77] | CSF | CSF pPKR predicts cognitive decline |
| Paquet et al. 2015 [79] | Brain | Aβ vaccine reduces pPKR load |
| Taga et al. 2017 [70] | Brain | Correlations cognitive scores and pPKR load |
Non-exhaustive list of published studies that assessed the levels of PKR signals in human AD samples, including brain, peripheral blood lymphocytes (PBL), and cerebrospinal fluid (CSF)